À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾

ÌõÄ¿µÄ

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÚÆß´ÎÈëÑ¡È«Çò¿ÉÁ¬ÐøÆóÒµ°ÙÇ¿

2023Äê1ÔÂ18ÈÕ £¬¼ÓÄôóÖªÃûýÌåºÍͶ×ÊÑо¿¹«Ë¾Corporate KnightsÐû²¼2023¡°È«Çò¿ÉÁ¬ÐøÉú³¤ÆóÒµ°ÙÇ¿¡± £¨2023 Global 100 Most Sustainable Corporations in the World£©¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉçλÁеÚ53λ £¬ÊÇÈ«ÇòÅÅÃû×î¸ßµÄÖÆÒ©ÆóÒµ¡£ÕâÊÇÒ²À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÚÆߴνøÈë°ÙÇ¿Ãûµ¥¡£

FDAÔÚ¿ìËÙͨµÀÈ϶¨ÏÂÅú×¼LEQEMBI?£¨lecanemab-irmb£©ÓÃÓÚÖÎÁÆ°¢¶û´Äº£Ä¬²¡

¼ÓËÙÉóÆÀÊÇ»ùÓÚIIÆÚÊý¾Ý £¬¸ÃÊý¾ÝÏÔʾÔÚ½ÓÊÜLEQEMBI?ÖÎÁƵÄÔçÆÚAD»¼ÕßÖеí·ÛÑù¦Â°ß¿éµÄ¼õÉÙ¡£
LEQEMBIµÄÖÎÁÆÓ¦¿ªÊ¼ÓÚÇá¶ÈÈÏÖªÕÏ°­»òÇá¶È³Õ´ô½×¶ÎµÄ»¼Õß £¬¼´ÔÚÁÙ´²ÊÔÑéÖпªÊ¼ÖÎÁƵÄÈËȺ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÔÚÖйúµÝ½»°¢¶û´Äº£Ä¬²¡ÖÎÁÆÒ©ÎïÂØ¿¨Ä¹ÉÏÊÐÉêÇë

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡Ðû²¼ £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÒÑÏòÖйú¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÌá½»ÂØ¿¨Ä¹£¨lecanemab £¬¿ª·¢´úºÅ: BAN2401£©ÉÏÊÐÉêÇë £¬ÂØ¿¨Ä¹ÊÇ°¢¶û´Äº£Ä¬²¡£¨AD£©ËùÖÂÇá¶ÈÈÏÖªÕÏ°­£¨MCI£©ºÍÇá¶ÈAD(ͳ³ÆΪÔçÆÚAD)µÄ¿¹µí·ÛÑùÂÑ°× (A¦Â) Ô­ÏËά¿¹Ìå¡£

°²Ë¹Ì©À´¡¢ÎäÌï¡¢µÚÒ»Èý¹²ºÍÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÅäºÏ¼õÉÙÓÉÒ©Æ·°ü×°Ëùµ¼ÖµĻ·¾³¸ºµ£

12ÔÂ22ÈÕ £¬°²Ë¹Ì©À´ÖÆÒ©¡¢µÚÒ»Èý¹²Öêʽ»áÉç¡¢ÎäÌïÖÆÒ©Öêʽ»áÉçºÍÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉçÅäºÏÐû²¼ £¬Ëļҹ«Ë¾ÒѸ濢ºÏ×÷ £¬½«ÅäºÏ¼õÉÙÓÉÒ©Æ·°ü×°Ëùµ¼ÖµĻ·¾³¸ºµ£¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«×ªÈÿ¹ñ²ðïÒ©ÎïFycompa? CIIIÔÚÃÀÉÌҵȨÀûתÈøøCatalystÖÆÒ©¹«Ë¾

12ÔÂ20ÈÕ £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓëCatalystÖÆÒ©¹«Ë¾¸æ¿¢Ð­Òé £¬½«À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¿¹ñ²ðïÒ©ÎïFycompa? CIIIÔÚÃÀ¹úµÄÉÌҵȨÀûתÈøøCatalystÖÆÒ©¹«Ë¾ £¬²¢ÎªÆäÌṩÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ñ²ðï¹ÜÏß²úÎï¶À¼Ò̸ÅÐÆÚ¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÔÚÃÀ¹úÒÔÍâµÄ¹ú¼ÒºÍµØÓò±£³ÖÆä¶ÔFycompa?µÄÉÌҵȨÀû £¬²¢¼ÌÐøΪñ²ðﻼÕß×ö³öТ¾´¡£Íê³É±¾´ÎתÈÃÈ¡¾öÓÚͨ¹ýÃÀ¹ú·´Â¢¶Ï·¨µÄÏà¹ØÉó²é¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Óëʥ·Ò×˹»ªÊ¢¶Ù´óѧҽѧԺ´ïÓñ³ÉÃæÑо¿ºÏ×÷ЭÒé £¬ÎªÉñ¾­ÍËÐÐÐÔ¼²²¡µÞÔìеÄÖÎÁÆÒªÁì

12ÔÂ15ÈÕ £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ó뻪ʢ¶Ù´óѧʥ·Ò×˹ҽѧԺ¸æ¿¢ÁËÒ»ÏîÈ«ÃæµÄÑо¿ºÏ×÷ЭÒé £¬Ö¼ÔÚΪ°üÂÞ°¢¶û´Äº£Ä¬²¡£¨AD£©ºÍÅÁ½ðÉ­²¡£¨PD£©ÔÚÄÚµÄÉñ¾­ÍËÐÐÐÔ¼²²¡µÞÔìDZÔÚµÄÐÂÐÍÖÎÁÆÒªÁì¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÔÚ2022ÄêÊ¥°²¶«Äá°ÂÈéÏÙ°©ÑÐÌÖ»áÉϽéÉÜ°¬Á¢²¼ÁÖµÄÏà¹ØÑо¿

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉç12ÔÂ1ÈÕÌåÏÖ £¬½«ÔÚ12ÔÂ6ÈÕÖÁ10ÈÕÓÚÃÀ¹úµÂ¿ËÈø˹ÖÝÊ¥°²¶«Äá°Â¾ÙÐеÄ2022ÄêÊ¥°²¶«Äá°ÂÈéÏÙ°©ÑÐÌÖ»á (SABCS)ÉÏÐû²¼Æä×ÔÖ÷Ñз¢µÄ¿¹°©Ò©Îï¼×»ÇËá°¬Á¢²¼ÁÖ£¨HALAVEN?£©µÄ×îÐÂÑо¿½á¹û¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÔÚ°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©»áÒéÉÏÐû²¼ÁËÂØ¿¨Ä¹ÑéÖ¤ÐÔIIIÆÚClarity-ADÑо¿¶ÔÔçÆÚ°¢¶û´Äº£Ä¬Ö¢µÄÈ«²¿½á¹û

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡½ñÈÕÐû²¼ £¬ÔÚ¼ÓÖݾɽðɽ¾ÙÐеÄ2022Äê°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©»áÒéÉÏ £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«Ðû²¼ÂØ¿¨Ä¹£¨¿ª·¢´úÂ룺BAN2401£©´óÐÍÈ«ÇòIIIÆÚÑéÖ¤ÐÔClarity ADÁÙ´²Ñо¿µÄ½á¹û £¬ÊÔÑéÒ©ÎïÂØ¿¨Ä¹ÊÇÖÎÁÆÄÔÄÚÈ·ÈÏ´æÔÚµí·ÛÑùÂѰײ¡ÀíµÄ°¢¶û´Äº£Ä¬²¡£¨AD£©ËùÖÂÇá¶ÈÈÏÖªÕÏ°­£¨MCI£©ºÍÇá¶ÈAD(ͳ³ÆΪÔçÆÚAD)µÄ¿¹µí·ÛÑùÂÑ°× (A¦Â) Ô­ÏËά¿¹Ìå¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÔÚµÚ15½ì°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©»áÒéÉÏչʾÂØ¿¨Ä¹LECANEMABÑéÖ¤ÐÔIIIÆÚÁÙ´²ÊÔÑ飨Clarity AD£©ºÍÆäËû°¢¶û´Äº£Ä¬²¡Ñо¿µÄÈ«²¿½á¹û

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉ罫ÔÚµÚ15½ì°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©»áÒéÉϽéÉÜÂØ¿¨Ä¹£¨lecanemab £¬¿ª·¢´úÂ룺BAN2401£©Clarity AD IIIÆÚÑéÖ¤ÐÔÁÙ´²ÊÔÑéµÄÁÆЧ¡¢Äþ¾²ÐÔºÍÉúÎï±êÖ¾Îï½á¹û £¬ÊÔÑéÒ©ÎïÂØ¿¨Ä¹ÊÇÖÎÁÆÄÔÄÚÈ·ÈÏ´æÔÚµí·ÛÑùÂѰײ¡ÀíµÄ°¢¶û´Äº£Ä¬²¡£¨AD£©ËùÖÂÇá¶ÈÈÏÖªÕÏ°­£¨MCI£©ºÍÇá¶ÈAD(ͳ³ÆΪÔçÆÚAD)µÄ¿¹µí·ÛÑùÂÑ°× (A¦Â) Ô­ÏËά¿¹Ìå¡£»áÒ齫ÓÚ11ÔÂ29ÈÕÖÁ12ÔÂ2ÈÕÔÚ¼ÓÖݾɽðɽ¾ÙÐÐ £¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍÏà¹ØÑо¿ÈËÔ±½«ÔÚ»áÒéµÚÒ»ÌìµÄ¿Æѧ»áÒéÉÏչʾȫ²¿Êý¾Ý£¨11ÔÂ29ÈÕÏÂÎç4:50 PT£©¡£´ËÍâ £¬À´×ÔÂØ¿¨Ä¹ÁÙ´²¿ª·¢ÏîÄ¿ºÍÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾AD¹ÜÏßµÄÆäËüÖØÒªÑо¿ £¬°üÂ޸ù«Ë¾ÕýÔÚÑо¿µÄ¿¹Î¢¹Ü½áºÏÇø£¨MTBR£©tau¿¹Ì壨E2814£© £¬½«Í¨¹ýËĸöÑݽ²Õ¹Ê¾ºÍÊ®¸öº£±¨Õ¹Ê¾½øÐнéÉÜ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¿¹ñ²ðïÒ© INOVELON? Âú×ãÈ«°¸ÀýÑо¿ÒªÇó

11ÔÂ2ÈÕ £¬ÈÕ±¾ºñÉúÀͶ¯Ê¡£¨MHLW£©½â³ýÁËÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¿¹ñ²ðïÒ©INOVELON?Ƭ¼Á100mgºÍ200mg£¨Í¨ÓÃÃû£ºrufinamide£©×÷ΪÆäËû¿¹ñ²ðïÒ©ÎAED£©µÄ¸¨ÖúÁÆ·¨ÓÃÓÚÖÎÁÆÂ×ŵ¿Ë˹-¼Ó˹ÍÐ×ÛºÏÕ÷£¨LSG£©Åú¼þÖÐËùÐèµÄÉÏÊкóÊÓ²ìÐÔÑо¿ £¬¼´È«°¸ÀýÑо¿µÄÒªÇó¡£

ÍøÕ¾µØͼ